A Phase 2 interventional study of TYNADOTE and Placebo Oral Tablet in Hepatitis, sponsored by Sinew Pharma Inc.. Recruiting at 1 site in Taiwan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2024-01-10.
Sponsored by Sinew Pharma Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Hepatitis with a site in Taiwan — 3 open to participants now, 4 under way, none of them phase 3. Hepatitis · Taiwan.
Among the 24 studies in Hepatitis with a site in Taiwan, this one is the 21st largest by planned enrollment of the 21 interventional ones that give a count, is the only one that started in 2023, is one of 9 in phase 2, and was the 20th registered.
344 studies on the registry are indexed under Hepatitis; 52 are open to participants now.
Browse Hepatitis studies →3 of the 24 studies in Hepatitis with a site in Taiwan are open now. Recruiting first, the newest first:
AusperBio Therapeutics Inc. · Sites in Taiwan, Australia, China and 3 more countries
Ages 18–65
Sinew Pharma Inc. · Sites in Taiwan
Ages 20–50 · Healthy volunteers
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 36 Hepatitis studies recruiting now, 23 (64%) set no upper age limit and 11 (31%) stop at 75 or younger; 6 take children under 18; 8 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 24 is below the median of 85 across 245 interventional studies indexed under Hepatitis.
Median enrollment 112 across the 21 interventional studies, 925 across the 2 observational. Of the 17 that completed or were terminated, 7 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 24 have an industry lead sponsor. The 10 most frequent:
Sinew Pharma Inc. is the lead sponsor of 8 studies on the registry; 4 are open to participants now.
Sinew Pharma Inc. has 2 studies filed under Hepatitis — fewer than ten, so there is no comparison to draw.
1 of the studies in Hepatitis with a site in Taiwan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05557448Sinew Pharma Inc.To Evaluate the Efficacy and Safety of TYNADOTE® in the Treatment of Acetaminophen Overdose | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 24 studies in Hepatitis with a site in Taiwan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate the efficacy and safety of TYNADOTE® in the treatment of acetaminophen overdose
This will be a 21-day study to evaluate the efficacy and safety of TYNADOTE® in the treatment of acetaminophen overdose.
After the inform consent is obtained from the subject or his/her legal guardians, the designated assessment will be performed. Subjects who fulfill all the inclusion and exclusion criteria will be eligible to enter the study. Except standard NAC antidote therapy, subjects would be randomized as 1:1 ratio to combine oral TYNADOTE® or placebo.
Eligible subjects will be randomized to receive oral TYNADOTE®/placebo combined iv NAC, and the regimen was listed as below:
The NAC intravenous loading dose is 150 mg/kg over a period of 15 to 60 minutes, followed by an infusion of 12.5 mg/kg per hour over a 4-hour period, and finally an infusion of 6.25 mg/kg per hour over a 16-hour period. Study drug, TYNADOTE® /placebo, should be given a loading dose of 400 mg, followed by 17 maintenance doses of 200 mg every 4 hours (Day 1 to Day 3).
During the treatment period, vital signs will be checked 15 minutes prior to dosing, 30 minutes, 60 minutes, then 2, 4, 8, 12, 24, 36, 48, 60 and 72 hours after first dosing. Blood samples will be collected for liver injuries and function test, including AST, ALT, total bilirubin, direct bilirubin and prothrombin time (INR), prior to dosing, 4 hours, 12 hours, 24 hours, 36 hours, 48 hours, 60 hours, 72 hours after first dosing. Blood samples for drug/metabolites concentration, including TYNADOTE® plasma concentration (trough level), plasma acetaminophen concentration, AAP-Cys and AAP-Cys adducts concentration, prior to dosing, 4 hours, 12 hours, 24 hours, 36 hours, 48 hours, 60 hours and 72 hours after first dosing. Blood samples for biochemistry and hematology, Day 1-3.
After completing the treatment (Day 3), subject will conduct the following evaluations before discharge:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
200 mg/every 4 hours, with a loading dose (400 mg) and then followed by 17 maintenance doses
Drug: TYNADOTE
200 mg/every 4 hours, with a loading dose (400 mg) and then followed by 17 maintenance doses
Drug: Placebo Oral Tablet
Subjects will take 200 mg/every 4 hours, with a loading dose (400 mg) and then followed by 17 maintenance doses
Subjects will take 200 mg/every 4 hours, with a loading dose (400 mg) and then followed by 17 maintenance doses
Alanine aminotransferase
Percentage change from baseline of ALT at Day 3.
Time frame: Day 3
Alanine aminotransferase
Percentage change from baseline of ALT at Day 7
Time frame: Day 7
Alanine aminotransferase
Percentage change from baseline of AST at Day 3, Day 7
Time frame: Day 7
Total bilirubin
Incidence of total bilirubin \> 2.5mg/dL at Day 3, Day 7, Day 21
Time frame: Day 3, Day 7 and Day 21
Inte- rnational Normalize Ratio
Incidence of INR \> 1.25 at Day 3, Day 7, Day 21
Time frame: Day 3, Day 7 and Day 21
Aspartate aminotransferase or Alanine aminotransferase
Incidence of AST or ALT \>1000 U/L at Day 3, Day 7, Day 21
Time frame: Day 3, Day 7 and Day 21
Hepatic failure rate (hepatic encephalopathy, ascites, total bilirubin, INR or liver transplantation)
Hepatic failure rate (hepatic encephalopathy, ascites, total bilirubin \>2.5mg/dL, INR \>1.25, or liver transplantation) at Day 7, Day 21
Time frame: Day 7 and Day 21
Mortality rate
Mortality rate at Day 7, Day 21
Time frame: Day 7 and Day 21
Free plasma acetaminophen-cysteine (AAP-Cys) and AAP-Cys adducts
The time-interval weighted area under the curve (AUC) of free plasma acetaminophen-cysteine (AAP-Cys) and AAP-Cys adducts within 72-hour treatment period
Time frame: Day 1-3
TYNADOTE® plasma concentration
The time-interval weighted area under the curve (AUC) of TYNADOTE® plasma concentration during 72-hour treatment period
Time frame: Day 1-3
Plan to share: Undecided
No publications or documents are linked to this record.
Started May 2023 (actual). Primary completion is estimated for Dec 2026, 43 months after the start.
Of 22 phase 2 interventional studies under Hepatitis, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 40. This study's planned 43 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sinew Pharma Inc.